期刊
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
卷 13, 期 9, 页码 1575-1576出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0960-894X(03)00201-4
关键词
-
资金
- NIAID NIH HHS [AI 33066] Funding Source: Medline
3'R,4'R-Di-O-(-)-camphanoyl-2',2'-dimethyldihydropyrano[2,3-f]chromone (DCP) (2) was designed and synthesized on the basis of a structure-activity relationship study of 3'R,4'R-di-O-(-)-camphanoyl-(+)-cis-khellactone DCK (1) and its analogues. DCP (2), a pyranochromone, and DCK (1), a pyranocoumarin, have different skeletons. Compound 2 showed potent in vitro inhibition of HIV-1 replication in H9 lymphocyte cells with an EC50 of 6.78 x 10(-4) muM and TI of 14,500. These values are comparable with those for DCK (1) and better than those of AZT in the same assay. (C) 2003 Elsevier Science Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据